tbuckley/cabot-search huggingface dataset:
Tumor site-specific silencing of NF-κB p65 by targeted hollow gold nanosphere-mediated photothermal transfection (Cancer Research (2010) 70, (3177-3188) DOI: 10.1158/0008-5472.CAN-09-3379)
Authors: W. Lu, Guodong Zhang, R. Zhang, L. G. Flores, Q. Huang, J. G. Gelovani, C. Li
Journal: Cancer Research (2010)
Maternal immunisation: collaborating with mother nature
Authors: Arnaud Marchant, Manish Sadarangani, Mathieu Garand, Nicolas Dauby, Valerie Verhasselt, Lenore Pereira, Gordean Bjornson, Christine E Jones, Scott A Halperin, Kathryn M Edwards, Paul Heath, Peter J Openshaw, David W Scheifele, Tobias R Kollmann
Journal: The Lancet Infectious Diseases (2017)
TCTAP C-178 Evaluation with Computed Tomography of Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy
Authors: Takamasa Tanaka, Atsunori Okamura, Hiroyuki Nagai, Akinori Sumiyoshi
Journal: Journal of the American College of Cardiology (2017)
Long-term follow-up of autologous hematopoietic stem cell transplantation for stage II/III breast cancer.
Authors: Andrew D. Meyer, Angelica L. Tolentino, Jacob D. Bitran, Leonard M. Klein
Journal: Journal of Clinical Oncology (2013)

7121 Background: In the 1980s and 1990s, adjuvant chemotherapy with high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) was utilized for the treatment of high-risk breast cancer. Previous studies showed that ASCT significantly reduced the risk of relapse in these patients, but failed to provide evidence of improved overall survival when compared with standard therapy in randomized trials. Due to the mortality, morbidity, and cost associated with ASCT and lack of a clear overall survival benefit, the use of HDC with ASCT for high-risk breast cancer was halted. In this retrospective, observation study, we analyzed the toxicity and efficacy of ASCT in high-risk breast cancer at a large community hospital. Methods: The study population consisted of 57 women diagnosed with high-risk primary breast cancer who underwent treatment with HDC followed by ASCT from 1991-1999. Women receiving treatment for metastatic breast cancer were excluded. The medical records of the study population were retrospectively reviewed, with particular attention to long-term toxicities and efficacy. Results: Fifty seven patients were evaluated: 54 with ductal and/or lobular breast cancer and 3 with inflammatory breast cancer. Median age was 44 years (29- 61). Twenty six patients (46%) were alive at time of review. Twelve patients (21%) experienced a recurrence of their breast cancer. Four patients (7%) developed secondary malignancies. Two patients (4%) experienced cardiac toxicities. Estrogen/progesterone receptor-positive breast cancers accounted for 42% of recurrences, 100% of secondary malignancies, and 50% of cardiac toxicities. HER-2/neu status analysis revealed amplification in 17% of breast cancer recurrences, but in no cases of secondary malignancy or cardiac toxicity. Conclusions: High-dose chemotherapy and ASCT can be effective in reducing long-term recurrences in women with high-risk, Stage II/III breast cancer. This treatment, however, carries an associated risk of secondary malignancies and cardiac toxicities. Estrogen/progesterone receptor-positive breast cancer appears to have a greater association with disease recurrence and secondary malignancies.
10-Year Outcomes in Localized Prostate Cancer
Authors: Freddie C Hamdy, Jenny L Donovan, David E Neal
Journal: New England Journal of Medicine (2017)

We agree with Klotz and Kibel that the lack of significant differences in survival among the three treatments makes a comparison between radiotherapy and surgery unwise. The predetermined power calculation for the ProtecT trial estimated a prostate-cancer mortality rate of 10% at a median of 10 years, and because the observed rate was 1%, longer follow-up is required to evaluate differences. We agree that the ProtecT findings should not be interpreted as a case against active surveillance. The similar rates of survival in the three groups, the lower rate of symptoms in the active-monitoring group than in the radical-treatment groups, and the finding that 80% of the men in the active-monitoring group remained progression- free provide evidence to support this option.
US deaths from cancer continue to fall
Authors: Michael McCarthy
Journal: BMJ (2017)

The overall rates of death from cancer in the United States have continued to fall while survival with most cancers has improved, a report has found.

The Annual Report to the Nation on the Status of Cancer, 1975-2014 showed a decline in mortality among men, women and children.1 Published online on 31 March in the Journal of the National Cancer Institute , it also found that death rates fell among all major racial and ethnic groups, although disparities persist.

The authors said that the decline in death rates reflected improvements in prevention, including a reduction in tobacco use, early detection—particularly of colorectal, breast, and cervical cancer—and better treatments.

The report is …
Dendritic cells expressing immunoreceptor CD300f are critical for controlling chronic gut inflammation
Authors: Ha-Na Lee, Linjie Tian, Nicolas Bouladoux, Jacquice Davis, Mariam Quinones, Yasmine Belkaid, John E. Coligan, Konrad Krzewski
Journal: Journal of Clinical Investigation (2017)

Proinflammatory cytokine overproduction and excessive cell death, coupled with impaired clearance of apoptotic cells, have been implicated as causes of failure to resolve gut inflammation in inflammatory bowel diseases. Here we have found that dendritic cells expressing the apoptotic cell-recognizing receptor CD300f play a crucial role in regulating gut inflammatory responses in a murine model of colonic inflammation. CD300f-deficient mice failed to resolve dextran sulfate sodium-induced colonic inflammation as a result of defects in dendritic cell function that were associated with abnormal accumulation of apoptotic cells in the gut. CD300f-deficient dendritic cells displayed hyperactive phagocytosis of apoptotic cells, which stimulated excessive TNF-α secretion predominantly from dendritic cells. This, in turn, induced secondary IFN-γ overproduction by colonic T cells, leading to prolonged gut inflammation. Our data highlight a previously unappreciated role for dendritic cells in controlling gut homeostasis and show that CD300f-dependent regulation of apoptotic cell uptake is essential for suppressing overactive dendritic cell-mediated inflammatory responses, thereby controlling the development of chronic gut inflammation.
Aortic Dilatation in Repaired Tetralogy of Fallot
Authors: Beatrice Bonello, Darryl F. Shore, Anselm Uebing, Gerhard-Paul Diller, Jennifer Keegan, Elisabeth D. Burman, Yumi Shiina, Lorna Swan, Dudley J. Pennell, Philip J. Kilner, Sylvain Beurtheret, Michael A. Gatzoulis, Sonya V. Babu-Narayan
Journal: JACC. Cardiovascular imaging (2017)
Abstract #677: Design, synthesis and preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine: Pentyl PABC-Doxaz
Authors: Daniel Chan, Benjamin Barthel, Zhiyong Zhang, Christopher Coldren, Tad Koch
Journal: Cancer Research (2009)

AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Doxazolidine (Doxaz) is the formaldehyde conjugate of doxorubicin (Dox) that induces cancer cell death in sensitive and MDR cells by cross-linking DNA. Doxaz is orders of magnitude more active than Dox but has a half-life of 3 min. under physiological conditions with respect to hydrolysis to Dox. A carboxylesterase 2-activted prodrug, pentyl PABC-Doxaz (PPD), was designed to be hydrolytically robust and to selectively deliver Doxaz to cancer cells that express the enzyme. Carboxylesterase 2 (CES2) is expressed in cytosol by liver, non-small cell lung, colon, pancreatic, renal, and thyroid cancer cells and is involved in the activation of the clinical prodrugs irinotecan and capecitabine. Cancer cell growth inhibition by PPD correlated with CES2 expression as indicated by gene array analysis. Hep G2 and N-Hep G2 hepatocarcinoma cells and H-1435 non small cell lung cancer cells were identified as highly responsive to PPD. NOD SCID mice were implanted s.c. with N-Hep G2 cells, and nude mice were implanted s.c. with H1435 cells. Tumor growth was monitored in i.v. dose escalation experiments versus no-drug and Dox controls. At termination, heart and liver sections were examined for evidence of cardio- and hepatotoxicity. Inhibition of tumor growth by PPD followed dose escalation and exceeded inhibition of tumor growth by doxorubicin near its maximum tolerated dose. In general PPD was well tolerated. Some weight loss with the maximum dose of PPD was observed at three weeks but mostly disappeared at five weeks. Heart sections of PPD-treated mice showed significantly less evidence of cardiotoxicity than heart sections of doxorubicin-treated mice. Liver sections showed more evidence of toxicity from PPD, consistent with hepatic expression of murine CES2. This study reports a strong rationale for further in vivo evaluation of PPD for treatment of tumors that express CES2.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 677.
Construction and Characterization of a Novel Ribonuclease Immunotoxin Consisting of Two Ranpirnase (Rap) Molecules Fused to an Internalizing Anti-CD74 Humanized IgG4 Antibody.
Authors: Sailaja S. Vanama, Puja Sapra, Hans J. Hansen, Ivan D. Horak, David M. Goldenberg, Chien-Hsing Chang
Journal: Blood (2004)
Increased salt consumption induces body water conservation and decreases fluid intake
Authors: Natalia Rakova, Kento Kitada, Kathrin Lerchl, Anke Dahlmann, Anna Birukov, Steffen Daub, Christoph Kopp, Tetyana Pedchenko, Yahua Zhang, Luis Beck, Bernd Johannes, Adriana Marton, Dominik N. Müller, Manfred Rauh, Friedrich C. Luft, Jens Titze
Journal: Journal of Clinical Investigation (2017)

The idea that increasing salt intake increases drinking and urine volume is widely accepted. We tested the hypothesis that an increase in salt intake of 6 g/d would change fluid balance in men living under ultra-long-term controlled conditions.Over the course of 2 separate space flight simulation studies of 105 and 205 days' duration, we exposed 10 healthy men to 3 salt intake levels (12, 9, or 6 g/d). All other nutrients were maintained constant. We studied the effect of salt-driven changes in mineralocorticoid and glucocorticoid urinary excretion on day-to-day osmolyte and water balance.A 6-g/d increase in salt intake increased urine osmolyte excretion, but reduced free-water clearance, indicating endogenous free water accrual by urine concentration. The resulting endogenous water surplus reduced fluid intake at the 12-g/d salt intake level. Across all 3 levels of salt intake, half-weekly and weekly rhythmical mineralocorticoid release promoted free water reabsorption via the renal concentration mechanism. Mineralocorticoid-coupled increases in free water reabsorption were counterbalanced by rhythmical glucocorticoid release, with excretion of endogenous osmolyte and water surplus by relative urine dilution. A 6-g/d increase in salt intake decreased the level of rhythmical mineralocorticoid release and elevated rhythmical glucocorticoid release. The projected effect of salt-driven hormone rhythm modulation corresponded well with the measured decrease in water intake and an increase in urine volume with surplus osmolyte excretion.Humans regulate osmolyte and water balance by rhythmical mineralocorticoid and glucocorticoid release, endogenous accrual of surplus body water, and precise surplus excretion.Federal Ministry for Economics and Technology/DLR; the Interdisciplinary Centre for Clinical Research; the NIH; the American Heart Association (AHA); the Renal Research Institute; and the TOYOBO Biotechnology Foundation. Food products were donated by APETITO, Coppenrath und Wiese, ENERVIT, HIPP, Katadyn, Kellogg, Molda, and Unilever.
2006년 대한간학회 학술연구기금 당선과제 결과 및 중간결과보고 : 우리나라 급성 바이러스간염의 실태: 역학, 임상 특성 및 바이러스학적 특성과 심한 급성 B형간염 및 C형간염 환자에서 항바이러스 치료의 효과
Authors: 정숙향, 황성규, 박상종, 강숙경, 지영미
Journal: Clinical and Molecular Hepatology (2007)
Declining Melanoma Rates in New England States
Authors: Stephen A. Fine
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Polycyclic Aromatic Hydrocarbons and Cancer in Man
Authors: Giuseppe Mastrangelo, Emanuela Fadda, Vita Marzia
Journal: Environmental Health Perspectives (1996)

Various substances and industrial processes, surrogates of exposure to polycyclic aromatic hydrocarbons (PAHs), are currently classified as human carcinogens. This paper reviews recent epidemiological studies reporting direct evidence of the carcinogenic effects of PAHs in occupationally exposed subjects. Risks of lung and bladder cancer were dose dependent when PAHs were measured quantitatively and truly nonexposed groups were chosen for comparison. These new findings suggest that the current threshold limit value of 0.2 mg/m3 of benzene soluble matter (which indicates PAH exposure) is unacceptable because, after 40 years of exposure, it involves a relative risk of 1.2-1.4 for lung cancer and 2.2 for bladder cancer.
Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL) with Hypercvad Based Regimens
Authors: Preetesh Jain, Hagop M. Kantarjian, Farhad Ravandi, Rashmi Kanagal-Shamanna, Joseph D Khoury, Keyur P. Patel, Guillermo Garcia-Manero, Marina Konopleva, Nitin Jain, Koji Sasaki, Tapan M. Kadia, Gautam Borthakur, Rebecca Garris, Sherry Pierce, Zeev Estrov, William G. Wierda, Jorge E. Cortes, Susan M. O'Brien, Elias J. Jabbour
Journal: Blood (2016)
Blood Transketolase Activity in Beriberi Heart Disease
Authors: Mohammed Akbarian
Journal: JAMA (1968)

Beriberi heart disease, a cardiac disorder due to a deficiency of thiamine, is relatively rare, and its diagnosis is commonly missed. The estimation of blood transketolase activity, a simple, sensitive, and specific assay which can detect significant thiamine deficiency, has been useful in establishing a diagnosis of beriberi heart disease. An acute form of high-output cardiac decompensation developed in five chronic alcoholic, inadequately nourished patients. In each case, blood transketolase determinations prior to therapy showed clear evidence of moderately severe thiamine deficiency. The enzyme assay is useful as a diagnostic tool in heart disease and a variety of nutritional disorder.
Peroxisome Proliferator Activated Receptor. Gene Expression In The Airways Of Non Cystic Fibrosis Bronchiectasis Subjects Is Lower Than Healthy Controls And Inversely Correlated To Total Pseudomonas AerugINOSa Bacterial Load At Baseline Entry Into A Clinical Trial
Authors: L. D. Burr, G. Rogers, A. Chen, M. McGuckin, D. J. Serisier
Journal: American Journal of Respiratory and Critical Care Medicine (2014)
Endoscopic Ultrasound Liver Biopsies Accurately Predict the Presence of Fibrosis in Patients With Fatty liver
Authors: Sammy Saab, Jennifer Phan, Melissa A. Jimenez, Jonathan F. Grotts, Laura Walters, Kelli A. Hathaway, Ketul R. Patel, Ali Lankarani, Michael Herman, David A. Holloman, Jose M. Nieto
Journal: Clinical Gastroenterology and Hepatology (2017)
Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study
Authors: Wojciech Jurczak, Pier Luigi Zinzani, Gianluca Gaidano, Andre Goy, Mariano Provencio, Zsolt Nagy, Tadeusz Robak, Kami J. Maddocks, Christian Buske, Sumeet Ambarkhane, Mark Winderlich, Maren Dirnberger-Hertweck, Jan Endell, Kristie A Blum
Journal: Blood (2016)
Comment on O’Brien et al. Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes. Diabetes Care 2017;40:233–238
Authors: Alain Braillon
Journal: Diabetes Care (2017)

O'Brien et al. (1) must be commended for evaluating the risk of thromboembolism among women with type 1 or 2 diabetes using hormonal contraception. Indeed, their study is robust and the drug safety issue too frequently overlooked.

However, their conclusion that “the absolute risk of thromboembolism among women with type 1 or 2 diabetes …
Cediranib (AZD2171) in docetaxel-resistant, castration-resistant prostate cancer (CRPC)
Authors: J. J. Karakunnel, J. L. Gulley, P. Arlen, M. Mulquin, J. Wright, I. B. Turkbey, P. Choyke, W. D. Figg, W. Dahut
Journal: Journal of Clinical Oncology (2009)

5141 Background: There is no standard therapy for prostate cancer patients who have progressed following docetaxel therapy. VEGF is implicated in tumor blood vessel formation and in disease progression in several solid tumors. Cediranib is an oral, small molecule inhibitor of receptor tyrosine kinases which influence VEGF. Methods: Patients must have clinical and/or radiographic evidence of progression on docetaxel with no limit on the number of prior chemotherapy regimens or radioisotopes. The starting dose is 20 mg daily, imaging is every 2 months. The primary objective is a 30% 6 month probability of progression free survival as determined by clinical (not by PSA rise alone) and radiographic criteria Simon two stage optimal design is being utilized with twelve patients enrolled in the first cohort. If 2 or more patients are progression-free at 6 months, the cohort will be expanded to 35 evaluable patients. Patients receiving cediranib were scanned by DCE-MRI pre- and post-treatment. A two compartment model was used to analyze the volume transfer. Results: Thirty-four of a planned 35 patients have been enrolled and 4 remain on active treatment (2–7 months). There have been 13 of 23 evaluable patients with tumor shrinkage and 4 have met the criteria for partial response. Decreases in lymph node metastases as well as in lung, liver and bone lesions have occurred. PSA levels have not corresponded well with imaging responses. Adverse events have been similar to other drugs in this class including hypertension, dysphonia and fatigue. Grade 3 toxicities included vomiting (2), prolonged QTc interval (1) and muscle weakness (3), weight loss (3), dehydration (4), fatigue (6), hypoxia (1), renal failure (1), transaminitis (3), and anorexia (1). There have been 30 patients who were evaluated by DCE-MRI. Targeted lesions included bone (17) and soft tissue (15). Conclusions: The safety profile and early activity makes cediranib a promising drug in CRPC post docetaxel. Preliminary data suggests that cediranib does have direct effect on the microcirculation and vasculature. Additional accrual is required to better characterize the response rate, the discrepancy between PSA and standard imaging changes and establish evidence of clinical correlation for DCE-MRI. No significant financial relationships to disclose.
Diagnostic and prognostic role of circulating <i>miR-206</i> in rhabdomyosarcoma patients.
Authors: Mitsuru Miyachi, Kunihiko Tsuchiya, Yoshihiro Nitta, Kazutaka Ouchi, Hideki Yoshida, Ken Kikuchi, Yasumichi Kuwahara, Tomoko Iehara, Hajime Hosoi
Journal: Journal of Clinical Oncology (2015)

10038 Background: miR-206 is a muscle-specific microRNA and is much more strongly expressed in rhabdomyosarcoma (RMS) tumors than in non-RMS tumors. Here, we analyzed the diagnostic and prognostic significance of circulating miR-206 values in serum specimens of RMS patients. Methods: Total RNA was extracted from serum samples (200 μL) from 60 patients (28 RMS, 32 non-RMS) and quantified by real-time quantitative RT-PCR. Receiver-operating characteristics (ROC) curves were established to evaluate the diagnostic value. Survival curves for RMS patients were calculated by the Kaplan-Meier method and were compared using the log-rank test. The median follow-up time was 30 months. Serum miR-206 expression level and prognostic factors were evaluated with a univariate analysis. The factors included age, primary tumor size, regional lymph node involvement, distant metastasis, fusion gene status, histologic subtype and primary tumor site. A multivariate analysis was conducted using the Cox proportional hazards regression method. The variables correlated with progression-free survival (PFS) in the univariate analysis were included in the model. Results: Serum miR-206 expression levels were higher in RMS patients than in non-RMS patients (p < 0.001) with an area under the ROC curve of 0.8705 (95% confidence interval [CI], 0.7791-0.962), sensitivity of 0.714 and specificity of 0.938. The cut-off value was 164.1 copies/μl serum. PFS was negatively influenced by a high serum miR-206 expression level (2.5-year PFS; 10.7 % (n = 14) vs 77.9 % (n = 14), p = 0.0019) and the presence of both distant metastasis and locoregional lymph node involvement (2.5-year PFS; 30.9 % (n = 18) vs 80.0 % (n = 10), p = 0.017) in univariate analysis. In the multivariate analysis, a high serum miR-206 expression level had an independent prognostic significance (hazard ratio: 3.50 [95% CI: 1.12-11.0], p = 0.031). Conclusions: miR-206 can be a novel biomarker for both diagnosis and treatment stratification of RMS. The limitations of our study include a retrospective design, small sample size and non-uniform treatment. The Japan Rhabdomyosarcoma Study Group will prospectively validate its prognostic significance in a large cohort of uniformly-treated patients.
Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma
Authors: Surya Nagaraja, Nicholas A. Vitanza, Pamelyn J. Woo, Kathryn R. Taylor, Fang Liu, Lei Zhang, Meng Li, Wei Meng, Anitha Ponnuswami, Wenchao Sun, Jie Ma, Esther Hulleman, Tomek Swigut, Joanna Wysocka, Yujie Tang, Michelle Monje
Journal: Cancer Cell (2017)
Burden of hip fracture using disability-adjusted life-years: a pooled analysis of prospective cohorts in the CHANCES consortium
Authors: Nikos Papadimitriou, Konstantinos K Tsilidis, Philippos Orfanos, Vassiliki Benetou, Evangelia E Ntzani, Isabelle Soerjomataram, Annemarie Künn-Nelen, Ulrika Pettersson-Kymmer, Sture Eriksson, Hermann Brenner, Ben Schöttker, Kai-Uwe Saum, Bernd Holleczek, Francine D Grodstein, Diane Feskanich, Nicola Orsini, Alicja Wolk, Andrea Bellavia, Tom Wilsgaard, Lone Jørgensen, Paolo Boffetta, Dimitrios Trichopoulos, Antonia Trichopoulou
Journal: The Lancet Public Health (2017)

No studies have estimated disability-adjusted life-years (DALYs) lost due to hip fractures using real-life follow-up cohort data. We aimed to quantify the burden of disease due to incident hip fracture using DALYs in prospective cohorts in the CHANCES consortium, and to calculate population attributable fractions based on DALYs for specific risk factors.